Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer J. 2012 Nov-Dec;18(6):642-52. doi: 10.1097/PPO.0b013e3182756903.

Vaccines for pancreatic cancer.

Author information

1
The Sidney Kimmel Cancer Center, Skip Viragh Clinical Pancreatic Cancer Center, Aurora, CO, USA.

Abstract

Pancreatic ductal adenocarcinoma (PDA) remains a highly lethal disease; new therapeutic modalities are urgently needed. A number of immunotherapies tested in preclinical models have shown promise. Early-phase clinical trials have demonstrated evidence of immune activation that in some cases correlates with clinical response. Moreover, recent evidence delineates the intricate role of inflammation in PDA, even at its earliest stages. Pancreatic ductal adenocarcinoma is thus ripe for immunotherapy; however, significant challenges remain before success can be realized. Future studies will need to focus on the discovery of novel PDA antigens and the identification of the multiple immune suppressive pathways within the PDA tumor microenvironment that inhibit an effective PDA-targeted immune response. Technologies are now available to rapidly advance discovery. Rapid translation of new discoveries into scientifically driven clinical trials testing combinations of immune agents will likely continue to shift the procarcinogenic tumor environment toward the most potent anticancer response.

PMID:
23187853
PMCID:
PMC3539747
DOI:
10.1097/PPO.0b013e3182756903
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Support Center